Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Galicaftor/Navocaftor/ABBV-119 or Galicaftor/Navocaftor/ABBV-576 Combination Therapies in Subjects With Cystic Fibrosis Who Are Homozygous or Heterozygous for the F508del Mutation

NCT04853368 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT04853368
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04853368 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Galicaftor/Navocaftor/ABBV-119 or Galicaftor/Navocaftor/ABBV-576 Combination Therapies in Subjects With Cystic Fibrosis Who Are Homozygous or Heterozygous for the F508del Mutation
Lead sponsor
AbbVie
Phase
Phase 2
Overall status
Terminated
Start date
September 20, 2021
Completion date
June 5, 2023
Enrollment
48 (actual)
Sites
41

Conditions

As the registry lists them; a condition with its own page is linked.

cystic fibrosis (cf)